Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) and Editas Medicine (NASDAQ:EDIT – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.
Institutional and Insider Ownership
60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 8.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 1.9% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Aligos Therapeutics and Editas Medicine”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aligos Therapeutics | $6.00 million | 10.09 | -$87.68 million | ($13.32) | -1.27 |
| Editas Medicine | $61.76 million | 2.57 | -$153.22 million | ($2.56) | -0.75 |
Profitability
This table compares Aligos Therapeutics and Editas Medicine’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aligos Therapeutics | -1,283.19% | -114.34% | -64.58% |
| Editas Medicine | -340.96% | -80.13% | -50.99% |
Risk & Volatility
Aligos Therapeutics has a beta of 2.45, indicating that its stock price is 145% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for Aligos Therapeutics and Editas Medicine, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aligos Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Editas Medicine | 2 | 9 | 3 | 0 | 2.07 |
Aligos Therapeutics presently has a consensus target price of $75.00, suggesting a potential upside of 344.58%. Editas Medicine has a consensus target price of $6.83, suggesting a potential upside of 255.90%. Given Aligos Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Editas Medicine.
Summary
Editas Medicine beats Aligos Therapeutics on 8 of the 14 factors compared between the two stocks.
About Aligos Therapeutics
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
About Editas Medicine
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
